TY - JOUR T1 - The intensity of COVID-19 outbreaks is modulated by SARS-CoV-2 free-living survival and environmental transmission JF - medRxiv DO - 10.1101/2020.05.04.20090092 SP - 2020.05.04.20090092 AU - C. Brandon Ogbunugafor AU - Miles Miller-Dickson AU - Victor A. Meszaros AU - Lourdes M. Gomez AU - Anarina L. Murillo AU - Samuel V. Scarpino Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090092.abstract N2 - COVID-19 has circled the globe, rapidly expanding from an outbreak in China to a pandemic in a matter of weeks. Lacking an effective vaccine or proven, pharmaceutical therapy, countries have enacted an unprecedented series of non-pharmaceutical interventions to combat this disease. However, the potential for variation in free-living virus survival to modulate the efficacy of these interventions remains unclear. Using an empirically determined understanding of SARS-CoV-2 natural history and detailed, country-level case data, we elucidate how variation in free-living virus survival influences key features of COVID-19 epidemics. Our findings suggest that COVID-19’s basic reproductive number and other key signatures of outbreak intensity are modulated by transmission between infected individuals and the environment. In addition, country-level outbreaks vary in the degree to which environmental transmission appears to modulate COVID-19 dynamics. Summarizing, we propose that informed models of “sit and wait,” environmental transmission are essential in emerging outbreaks, as they highlight how variation in environmental transmission may explain observed differences in disease dynamics from setting to setting, and can inform public health interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementALM would like to acknowledge NIH U54GM115677 for funding support.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are either available or the source is referenced in the main text and supplemental information. The code used for the analyses in this study is publicly available on Github: https://github.com/OgPlexus/Copperland ER -